Atlas Trials

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Clinical trial NCT03415399 · COMPLETED

Trial details

NCT number
NCT03415399
Sponsor
Eureka Therapeutics Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma, B-Cell
Start date
2017-09-09
Primary completion
2020-12-31
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.